Latham & Watkins Advises Goldman Sachs Alternatives on US$1.6 Billion Sale of Vicebio to Sanofi

Vicebio Ltd (Vicebio), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi. Under the terms of the agreement, subject to customary conditions, Vicebio shareholders will receive up to a total of US$1.6 billion, including an upfront payment of US$1.15 billion as well as development and regulatory milestones payments of US$450 million.

Latham & Watkins LLP represents Goldman Sachs Alternatives in the transaction with a corporate deal team led by Bay Area partner Saad Khanani, with associate Jay Trewn.